These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 18435430

  • 21. Rare diseases and orphan drugs.
    Taruscio D, Capozzoli F, Frank C.
    Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Jumpstarting research into neglected diseases.
    Leslie M.
    Cell; 2006 Nov 03; 127(3):443-5. PubMed ID: 17081963
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D, Kremer M.
    Bull World Health Organ; 2001 Nov 03; 79(8):735-41. PubMed ID: 11545330
    [Abstract] [Full Text] [Related]

  • 27. EU orphan regulation--ten years of application.
    Michaux G.
    Food Drug Law J; 2010 Nov 03; 65(4):639-69, i-ii. PubMed ID: 24479246
    [Abstract] [Full Text] [Related]

  • 28. Drug development for orphan diseases in the context of personalized medicine.
    Brewer GJ.
    Transl Res; 2009 Dec 03; 154(6):314-22. PubMed ID: 19931198
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.
    Ned Tijdschr Geneeskd; 2012 Dec 03; 156(17):A4252. PubMed ID: 22531041
    [Abstract] [Full Text] [Related]

  • 33. A new era of hope for the world's most neglected diseases.
    The PLoS Medicine Editors.
    PLoS Med; 2005 Sep 03; 2(9):e323. PubMed ID: 16138790
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN, Kartavtsova TV.
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014 Sep 03; (3):37-42. PubMed ID: 25219041
    [Abstract] [Full Text] [Related]

  • 37. Orphan drugs: the regulatory environment.
    Franco P.
    Drug Discov Today; 2013 Feb 03; 18(3-4):163-72. PubMed ID: 22981668
    [Abstract] [Full Text] [Related]

  • 38. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME.
    Clin Pharmacol Ther; 2016 Oct 03; 100(4):342-3. PubMed ID: 27392514
    [Abstract] [Full Text] [Related]

  • 39. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct 03; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 40. New non-profit organization will support research to combat neglected diseases.
    Walgate R.
    Bull World Health Organ; 2002 Oct 03; 80(10):842-3. PubMed ID: 12471410
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.